'Functional unblinding was a major barrier to the approval of psychedelics as medicines to treat the patients who need them most,' said Dr. Andrew Chadeayne, CaaMTech CEO. 'I'm incredibly proud that ...

Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...

Atai Life Sciences N.V. ( (ATAI) ) has released its Q3 earnings. Here is a breakdown of the information Atai Life Sciences N.V. presented to ...

New research suggests that it could be possible to separate treatment from hallucinations when developing new drugs based on psychedelics. The anti-anxiety and hallucination-inducing qualities of ...

Computer-assisted cognitive-behavior therapy (CCBT) and mobile mental health applications warrant continued development and ...

New research suggests that it could be possible to separate treatment from hallucinations when developing new drugs based on ...

New research has identified distinct neural circuits for the anti-anxiety and hallucinogenic effects of psychedelics.

Tyson's experimentation with psychedelics, particularly the powerful substance known as "the toad", 5-MeO-DMT, has become a ...

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

The work by UB neuroscientists provides key insight into how the “lifesaving” medication offers almost instant relief of symptoms of major depression.